Online inquiry

IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3798MR)

This product GTTS-WQ3798MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Factor VIIa substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000131.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2155
UniProt ID P08709
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3798MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1577MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ9256MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ12742MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ15053MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ9840MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ6909MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ10504MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ14822MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW